english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2019 > The Prescrire Drug Awards for 2019 > 2019 Drug Awards

The Prescrire Awards for 2019

The Prescrire Drug Awards for 2019

The Prescrire Drug Awards for 2019

Les Palmarès Prescrire Three drugs made the Honours List and three others were recognised as Noteworthy, but there was no "Pilule d'Or" ("Golden Pill") awarded this year.


Three drugs were placed on the "Honours List", since they were found to constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations: 

  • HEMLIBRA° (emicizumab) Roche
    Prophylaxis of bleeding episodes in patients with haemophilia A and "factor VIII inhibitors"
     
  • KYMRIAH° (tisagenlecleucel) Novartis
    B-cell acute lymphoblastic leukaemia in children and young adults when other treatment options have been exhausted
     
  • YESCARTA° (axicabtagene ciloleucel) Kite Pharma (a Gilead company)
    Certain types of large B-cell lymphomas when other treatment options have been exhausted 

Drugs that were deemed "Noteworthy" provide a modest improvement in patient care:

  • JAKAVI° (ruxolitinib) Novartis
    Symptomatic myelofibrosis
     
  • KADCYLA° (trastuzumab emtansine) Roche
    HER2-positive inoperable breast cancer in women who previously received trastuzumab and a taxane
     
  • KEYTRUDA° (pembrolizumab) MSD
    Metastatic non-small cell lung cancer, as first-line treatment
For details, download the complete review:

 FREE  "The Prescrire Awards for 2019" Prescrire Int 2020; 29 (213): 77-81. (Pdf, free)

> Rules governing the Prescrire Awards (pdf, in French)

Back to the contents page for the 2019 Prescrire Awards >

 ©Prescrire 1 February 2020 Share Share on Facebook Share on Twitter